Rystiggo (Rozanolixizumab-noli) for Myasthenia Gravis

Overview
Rystiggo is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults diagnosed with generalized myasthenia gravis who are anti-acetylcholine receptor positive or anti-muscle-specific tyrosine kinase antibody positive. Rystiggo is also referred to by its drug name, rozanolixizumab-noli.

Rystiggo is a member of a class of drugs called Fc receptor blockers. It’s believed to work by reducing how much of an antibody called immunoglobulin G (IgG) is circulating in the body. IgG attacks neuromuscular receptors in people with myasthenia gravis.

How do I take it?
Prescribing information states that Rystiggo is administered as a subcutaneous (under the skin) infusion. The label recommends that dosages — determined based on the recipient’s body weight — be administered once weekly for six weeks.

Side effects
The FDA-approved label for Rystiggo lists the following as common side effects: headache, infections, diarrhea, fever, hypersensitivity reactions, and nausea.

Rare but serious side effects listed for Rystiggo include infections, aseptic meningitis, and hypersensitivity reactions — specifically swelling beneath the skin and rash.

For more details about this treatment, visit:

Rystiggo — UCB
https://www.rystiggohcp.com/

Rystiggo — Drugs.com
https://www.drugs.com/rystiggo.html